Accurate detection of PIK3CA mutations is essential for personalizing breast cancer treatment, particularly with PI3K-targeted therapies. 

Chemokines, acting as "traffic controllers" in the tumor microenvironment, regulate immune cell infiltration and local immunity. This review summarizes the chemokine expression profiles in tumors, their diverse roles in pro- and anti-tumor immunity, current targeting strategies (inhibition, delivery, engineering), and synergistic potential ability with other immunotherapies. Despite challenges, targeting the chemokine receptor axis holds great promise for reprogramming the tumor microenvironment and advancing precision cancer therapy.

“In other words, a very high number of women are being unnecessarily treated,” explains CNIO researcher Eva González-Suárez. “But at the moment there’s no way to avoid it”.

Her new study, published in Nature Communications, identifies a marker that discriminates precancerous breast lesions that will develop into tumours

The study also reveals that breast cancers originate in certain cells that the authors refer to as ‘infidel’